FTC expands PBM investigation to include rebate negotiators

The Federal Trade Commission, which this week sued to block Amgen’s $28 billion buyout of Horizon, is simultaneously expanding its probe into dubious practices from pharmacy benefit managers by going after two group purchasing organizations (GPOs) that negotiate drug rebates on behalf of PBMs. The compulsory orders issued by the…

Click to view original post